CA-GLOBALLOGIC
11.5.2022 14:02:10 CEST | Business Wire | Press release
GlobalLogic Inc. , a Hitachi Group company and leader in Digital Engineering, has launched the Women Influencers Program, designed to encourage and enable women employees interested in exploring cross-functional management positions within the technology firm. As part of the company’s focus on DEI (Diversity, Equity, Inclusion), GlobalLogic is aiming for greater diversity at all levels in the workforce across gender, sexual orientation, color, ethnic origin, age and ability. The Women Influencers Program is specifically focused to promote greater gender diversity especially among the company’s leadership ranks. The Program will provide developmental and mentoring opportunities through GlobalLogic’s People Development function and individual business units.
Core Program Elements
The Program centers around nine competencies that participants will explore via a set of learning modules, with an entire Program journey expected to last five to six months. Operating in tandem, global cohorts of women based across the globe will join together to share and learn from collective experiences.
The competencies promote the development of “soft” skills – meaning those not directly tied to a formal educational program but rather gained through experience and from peers. These competencies include directness and candor, inspiring and influencing others, effective decision making, professional network development, and the continued development of communication skills. Program participants will also receive training specific to GlobalLogic’s capabilities which are meant to enhance essential corporate knowledge and increase depth of technical competencies.
"Diversity, equity, and inclusion are paramount to GlobalLogic's success," said Amy Hanlon-Rodemich, Chief People Officer, GlobalLogic. "We created the Women Influencers Program to elevate emerging women leaders and to prepare them to take on a wider range of roles and responsibilities including expansion into senior leadership roles. This Program will enable more women leaders to take on more strategic positions within the company."
Based on Research
Initially piloted in India in 2020, the Program’s intent was to actively focus on enhancing the company’s management pipeline with a consideration toward diversity and inclusivity; particularly for women within the company. Upon conducting in-depth analysis of leadership roles and paths to those positions, GlobalLogic’s Program development team discovered that while the digital engineering firm’s overall diversity stats were above the industry average, an even more diverse senior management team would be a tremendous enhancement to the current management ranks.
Research suggests that the female-to-male disparity is due to multiple factors, including prioritization of personal and family life, cultural demands and differences, and organizational dynamics. It was also noted that many women express a distinct “burn out” effect, indicating an ongoing struggle to identify resources and opportunities for progressing their careers.
In response, the Program development team explored options for accelerating women’s career paths by developing essential leadership skills and helping them becoming future ready, positioning participants to take on new roles within GlobalLogic.
“Our aim is to correct the imbalance in women holding leadership roles versus men, which is common throughout the technology industry according to global statistics,” said Shivani Khanna, Senior Manager, People Team, GlobalLogic. “We believe that through our Program’s structured guidance and encouragement, we can positively shift that dynamic.”
Establishing a Supportive Ecosystem
The ecosystem being developed by GlobalLogic will include “Anchors,” a role held by members of the human resources team who will help ensure that the Program is operating effectively. Anchors will also manage the learning and mentor groups that will spearhead the specific activities designed to provide the professional skills previously referenced.
Participants’ managers will be enlisted as “Program Catalysts” responsible for ensuring that the Program is not simply a training exercise but rather a complete learning journey championing employee learning and advancement across the organization.
“Program Sponsors — the managers and mentors — will act as coaches overseeing the employees’ journeys. They will help steer participants toward the content and activities appropriate to each individual’s unique path,” Khanna continued. “We’re excited to officially launch this Program in GlobalLogic locations around the world.”
About GlobalLogic
GlobalLogic (www.globallogic.com ) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220511005037/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
